Form 4: Supernus Pharmaceuticals Executive Reports Changes in Beneficial Ownership

Frank Mottola, SVP at Supernus Pharmaceuticals, reports acquisition of shares through employee stock purchase plan and performance share units.

Summary

• Frank Mottola, SVP of Quality, GMP, Ops, and IT at Supernus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates that Mottola acquired 251 shares of common stock through the company's Employee Stock Purchase Plan.
• Additionally, Mottola was awarded 1,125 Performance Share Units on February 22, 2024, which vested upon achievement of individual performance objectives established on June 24, 2024.
• Following these transactions, Mottola directly owns 8,451 shares of Supernus Pharmaceuticals common stock and 1,125 Performance Share Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard regulatory filing. The executive's participation in the employee stock purchase plan and vesting of performance share units are mildly positive signals.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan demonstrates the executive's investment in the company's future.
• The vesting of Performance Share Units based on individual performance objectives aligns executive compensation with company goals.

Industry Context

Form 4 filings are a routine part of the US financial market, providing transparency into the transactions of company insiders. This filing indicates the executive's continued investment in the company.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive stock ownership.
• The executive's participation in the employee stock purchase plan could be viewed positively by employees.

Key Dates